Description
Tirzide 15 MG (Tirzepatide) is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist the world’s first and only approved twincretin supplied as a 15 mg solution for injection in a pre-filled syringe (1 syringe/box with alcohol pad and first aid bandage) and manufactured by Everest Pharmaceuticals Ltd. in Bangladesh. Its active ingredient, tirzepatide INN, simultaneously activates both the GIP receptor and the GLP-1 receptor in a single once-weekly subcutaneous injection delivering the most comprehensive dual incretin receptor engagement available in any approved pharmacological agent.
The 15 mg dose of tirzepatide is the maximum approved maintenance dose and the ceiling of the reference-label titration schedule prescribed subcutaneously once weekly for adults with type 2 diabetes mellitus (T2DM), chronic weight management in adults with obesity or overweight, and moderate to severe obstructive sleep apnea (OSA) in adults with obesity, each indication representing a separate and clinically validated approval for tirzepatide 15 mg based on Phase 3 trial evidence. In the pivotal SURPASS-2 Phase 3 trial (n=1,879 adults with T2DM on background metformin), tirzepatide 15 mg produced a mean HbA1c reduction of 2.30% and a mean body weight reduction of 11.2 kg from baseline versus 1.86% HbA1c and 5.7 kg weight reduction with semaglutide 1 mg at 40 weeks (p<0.001 for both) the largest glycemic and weight reduction outcomes ever documented in a head-to-head incretin trial.
In the landmark SURMOUNT-1 Phase 3 trial (n=2,539 adults with obesity or overweight without T2DM), tirzepatide 15 mg produced a mean body weight reduction of 22.5% from baseline versus 2.4% with placebo at 72 weeks the largest pharmacological weight loss ever recorded in a randomized controlled trial, with 48% of patients achieving ≥25% body weight loss. Searching for Tirzide 15 MG Tirzepatide? Mediaid Pharmacy lists this product within its comprehensive diabetes medicines portfolio and ships it worldwide.
Basic Product Information of Tirzide 15 MG (Tirzepatide)
| Brand Name | Tirzide 15 MG (Tirzepatide) |
| Product Name | Tirzide |
| Generic Name | Tirzepatide INN |
| Drug Class | Dual GIP (Glucose-Dependent Insulinotropic Polypeptide) and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonist; Twincretin; Antidiabetic Agent; Anti-Obesity Agent; Incretin-Based Therapy; OSA Treatment Agent |
| Formulation | Solution for Injection (Pre-filled Syringe) |
| Available Strength | 15 mg (Maximum Approved Dose) |
| Available Pack Size | 1 Pre-filled Syringe/Box (with alcohol pad & first aid bandage) |
| Primary Indications & Dose Position | Type 2 diabetes mellitus (T2DM) in adults as an adjunct to diet and exercise for improved glycemic control: maximum maintenance dose 15 mg subcutaneously once weekly, reached by titrating from 2.5 mg (initiation) through 5 mg, 7.5 mg, 10 mg, and 12.5 mg in 2.5 mg increments at ≥4-week intervals (minimum 20 weeks of prior tirzepatide exposure). Chronic weight management as an adjunct to reduced-calorie diet and increased physical activity in adults with BMI ≥30 kg/m² (obesity) or ≥27 kg/m² (overweight) with at least one weight-related comorbidity: same 15 mg maximum dose and titration schedule. Moderate to severe obstructive sleep apnea (OSA) in adults with obesity: 15 mg is one of the two specifically recommended maintenance doses (alongside 10 mg). The 15 mg dose is the ceiling of the tirzepatide titration schedule; no further dose escalation is permitted above this level. |
| Manufacturer | Everest Pharmaceuticals Ltd., Bangladesh |
| Registration | Bangladesh |
| Originator Reference Brand | Mounjaro (tirzepatide) by Eli Lilly for type 2 diabetes; Zepbound (tirzepatide) by Eli Lilly for chronic weight management and obstructive sleep apnea |
| Global Supplier | Mediaid Pharmacy, Worldwide Shipping Available |
| Storage Conditions | Store at 2°C to 8°C (refrigerated). Do not freeze. Protect from light. If stored at room temperature (up to 30°C/86°F), use within the period stated on the pack. Keep out of the reach of children. |
How Tirzide 15 MG (Tirzepatide) Works: Maximum Dual GIP and GLP-1 Receptor Agonism Peak Twincretin Efficacy at the Approved Ceiling Dose
Tirzepatide, the active ingredient in Tirzide 15 MG, is the world’s first approved dual GIP and GLP-1 receptor agonist a pharmacological class defined by the simultaneous activation of two distinct incretin hormone receptors within a single molecule, administered as a once-weekly subcutaneous injection. At the 15 mg maximum dose, tirzepatide achieves its ceiling pharmacodynamic effect full and sustained dual engagement of both the GIP (glucose-dependent insulinotropic polypeptide) receptor and the GLP-1 (glucagon-like peptide-1) receptor at the highest approved exposure level delivering the broadest and most comprehensive twincretin action available in any approved antidiabetic or anti-obesity agent.
This mechanistic ceiling position distinguishes tirzepatide 15 mg from every other approved incretin-based therapy: selective GLP-1 receptor agonists including semaglutide, liraglutide, dulaglutide, and exenatide activate only the GLP-1 receptor, while tirzepatide 15 mg activates both receptors simultaneously through their respective and pharmacologically distinct intracellular signaling cascades, producing an additive and in multiple metabolic parameters synergistic pharmacodynamic profile that accounts for tirzepatide’s consistently superior glycemic and weight management outcomes across the entire SURPASS and SURMOUNT Phase 3 clinical trial programs. GIP (glucose-dependent insulinotropic polypeptide) is a gut-derived incretin peptide hormone secreted postprandially from intestinal K-cells; GLP-1 (glucagon-like peptide-1) is similarly secreted postprandially from intestinal L-cells.
Together, these two hormones constitute the physiological incretin system responsible for 50 to 70% of postprandial insulin secretion in metabolically healthy individuals an incretin effect severely impaired in type 2 diabetes mellitus (T2DM) due to GIP receptor desensitization under chronic hyperglycemia and diminished GLP-1 secretion from dysfunctional L-cells. The pharmacological restoration of both incretin receptor signaling axes at full dual receptor engagement through tirzepatide 15 mg represents the most complete pharmacological correction of the incretin deficit driving postprandial hyperglycemia in T2DM achievable with any approved agent.
At the 15 mg maximum maintenance dose, tirzepatide’s GLP-1 receptor agonism engages four established and complementary antidiabetic mechanisms at its pharmacological ceiling: (1) glucose-dependent stimulation of pancreatic beta-cell insulin secretion the glucose-conditionality of this effect means insulin is released only when plasma glucose exceeds the physiological threshold, providing mechanistic protection against hypoglycemia as monotherapy; (2) glucose-dependent suppression of pancreatic alpha-cell glucagon secretion, reducing both fasting and postprandial hepatic glucose output that drives the persistent hyperglycemia of advanced T2DM; (3) maximal slowing of gastric emptying sustained and consistent at the 15 mg ceiling dose after progressive GI adaptation across the titration schedule blunting the postprandial glucose excursion by decelerating carbohydrate delivery to the small intestine absorption site; and (4) hypothalamic and brainstem GLP-1 receptor activation at maximum agonist occupancy, producing peak anorexigenic signaling in the arcuate nucleus and nucleus tractus solitarius that suppresses appetite, reduces meal frequency and portion size, and drives the sustained caloric deficit responsible for tirzepatide 15 mg’s unprecedented pharmacological weight loss outcomes.
Tirzepatide’s GIP receptor agonism at 15 mg contributes peak pharmacodynamic effects across three orthogonal metabolic pathways: maximum GIP receptor-mediated amplification of glucose-stimulated insulin secretion in pancreatic beta-cells through cAMP-PKA signaling cascades that are structurally and pharmacologically independent of GLP-1 receptor-coupled adenylyl cyclase activation, producing the additive insulinotropic effect that mechanistically explains tirzepatide’s HbA1c reductions of 2.30% at 15 mg measurably larger than any HbA1c reduction ever documented for a selective GLP-1 receptor agonist at its maximally approved dose; maximum GIP receptor-mediated modulation of adipose tissue lipid metabolism through promotion of lipoprotein lipase-mediated triglyceride clearance and enhancement of fatty acid re-esterification, contributing to tirzepatide 15 mg’s preferential visceral fat reduction and superior hepatic steatosis reversal beyond that attributable to body weight loss alone; and maximum central GIP receptor engagement in hypothalamic appetite circuits that amplifies the anorectic effect of GLP-1 receptor co-activation through distinct and additive neuronal signaling pathways.
Clinicians managing patients who require the maximum tirzepatide dose for complex T2DM, severe obesity, or obstructive sleep apnea can review the full tirzepatide medicines range at Mediaid Pharmacy for their prescribing programs.
Tirzide 15 MG delivers the 15 mg maximum maintenance dose of tirzepatide as a ready-to-inject pre-filled syringe administered subcutaneously once weekly. Each box contains 1 pre-filled syringe with an alcohol pad and first aid bandage a complete single-injection kit for one week of maximum-dose maintenance therapy, requiring no reconstitution, dose calculation, or pen dialing. The 15 mg dose is reached through the reference-label structured titration schedule 2.5 mg (4 weeks) → 5 mg (≥4 weeks) → 7.5 mg (≥4 weeks) → 10 mg (≥4 weeks) → 12.5 mg (≥4 weeks) → 15 mg meaning that patients who reach Tirzide 15 MG have accumulated a minimum of 20 weeks (approximately 5 months) of continuous tirzepatide therapy with progressive gastrointestinal adaptation before the ceiling dose is introduced.
This 20-week titration prerequisite represents the most thorough GI adaptation history of any dose step in the schedule, substantially mitigating the nausea, vomiting, and diarrhea severity that would occur if 15 mg were administered without prior dose escalation. The pharmacokinetic profile of tirzepatide at 15 mg governed by the C20 fatty diacid conjugation and albumin-binding mechanism that extends the plasma half-life to approximately 5 to 6 days across all maintenance doses achieves steady-state plasma concentrations within 4 to 5 weeks of initiating the 15 mg dose, establishing the stable therapeutic exposure level at which the maximum glycemic, weight management, and OSA efficacy outcomes documented in Phase 3 trials are attained. Healthcare providers sourcing the full Tirzide dose range or companion diabetes medicines can explore the diabetes medicines portfolio at Mediaid Pharmacy for worldwide delivery.
The clinical evidence base for tirzepatide 15 mg is the most extensive and consequential across the tirzepatide dose range. In the SURPASS-1 Phase 3 trial (tirzepatide monotherapy vs. placebo in 478 adults with T2DM, 40 weeks), tirzepatide 15 mg produced a mean HbA1c reduction of –2.11% from a baseline of approximately 7.9% versus –0.04% with placebo (p<0.001), with 92% of patients reaching HbA1c below 7.0% and 51% achieving normoglycemic HbA1c below 5.7% rates of glycemic normalization unmatched by any previously approved antidiabetic agent or drug class in T2DM monotherapy. In SURPASS-3 (vs. insulin degludec titrated to fasting glucose targets, n=1,444, 52 weeks), tirzepatide 15 mg reduced HbA1c by –2.37% versus –1.34% with optimally titrated insulin degludec (p<0.001), while producing a body weight reduction of –12.9 kg versus a +2.3 kg weight gain with insulin degludec a combined glycemic and body weight advantage over best-practice basal insulin therapy that reframes the position of incretin therapy in T2DM treatment algorithms.
In SURMOUNT-2 (adults with T2DM and obesity, n=938, 72 weeks), tirzepatide 15 mg produced a mean body weight reduction of 15.7% from baseline versus 3.3% with placebo confirming that the maximum weight management efficacy of tirzepatide 15 mg is maintained in the diabetic obese population, where the glycemic and cardiometabolic burden of combined T2DM and obesity is highest.
Approved Indications of Tirzepatide 15 MG (Reference Label for Tirzide 15 MG (Tirzepatide))
Tirzepatide, the active ingredient in Tirzide 15 MG, carries reference-label approval across three distinct therapeutic indications the broadest clinical scope of any tirzepatide dose strength and the most expansive indication set approved for a single antidiabetic agent in the incretin class. The 15 mg dose is the maximum dose across all three approved indications and serves as the therapeutic ceiling that prescribers titrate toward when lower maintenance doses do not fully achieve individualized treatment targets.
No further dose escalation above 15 mg is permitted in any indication; the 15 mg dose represents the pharmacological and regulatory ceiling of tirzepatide therapy. Prescribers should confirm locally approved indications on the Tirzide 15 MG product label and applicable national diabetes, obesity, and sleep medicine clinical guidelines before initiating or continuing maximum-dose tirzepatide treatment.
|
Type 2 Diabetes Mellitus Maximum HbA1c Reduction with Tirzepatide 15 mg Once Weekly Indicated for adults with T2DM as an adjunct to diet and exercise to improve glycemic control. Tirzepatide 15 mg is the maximum dose for T2DM, prescribed for patients who have not achieved their individualized HbA1c target after ≥4 weeks at 12.5 mg, or for whom a prescribing endocrinologist determines that maximum tirzepatide efficacy is required from the outset of the titration plan. In SURPASS-1, 92% of patients achieved HbA1c below 7.0% and 51% reached normoglycemia (HbA1c below 5.7%) on tirzepatide 15 mg monotherapy. In SURPASS-2, tirzepatide 15 mg produced –2.30% HbA1c reduction versus –1.86% with semaglutide 1 mg (p<0.001; n=1,879). For companion antidiabetic agents alongside tirzepatide 15 mg, browse the diabetes medicines collection at Mediaid Pharmacy. |
Chronic Weight Management 22.5% Mean Body Weight Reduction: The Largest Pharmacological Weight Loss on Record Indicated for chronic weight management in adults with BMI ≥30 kg/m² (obesity) or ≥27 kg/m² (overweight) with at least one weight-related comorbidity as an adjunct to a reduced-calorie diet and increased physical activity. In SURMOUNT-1 (n=2,539 adults without T2DM, 72 weeks), tirzepatide 15 mg produced a mean body weight reduction of 22.5% from baseline versus 2.4% with placebo the largest mean weight loss ever documented in a randomized controlled pharmacological trial, with 48% of patients achieving ≥25% body weight loss and outcomes approaching those of bariatric surgery. In SURMOUNT-2 (T2DM + obesity), tirzepatide 15 mg produced 15.7% mean weight loss versus 3.3% placebo. For the full tirzepatide strength range, visit the tirzepatide medicines portfolio at Mediaid Pharmacy. |
Moderate to Severe Obstructive Sleep Apnea (OSA) with Obesity 15 mg as a Recommended Maintenance Dose Tirzepatide is the first pharmacological agent approved to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity, with 15 mg designated as one of the two recommended maintenance doses (alongside 10 mg). In the SURMOUNT-OSA Phase 3 trial, tirzepatide 15 mg significantly reduced the apnea-hypopnea index (AHI) the primary measure of OSA severity versus placebo, alongside clinically meaningful body weight reduction, improved nocturnal oxygen saturation, and reduced hypoxic burden. Tirzepatide’s OSA benefit at 15 mg is driven primarily through weight-mediated improvement in upper airway anatomy, with the maximum weight-reducing effect of the 15 mg ceiling dose delivering the greatest potential AHI reduction of any tirzepatide maintenance strength. Explore the Everest Pharmaceuticals medicines range at Mediaid Pharmacy. |
Key Clinical Benefits of Tirzide 15 MG (Tirzepatide)
|
Record-Breaking HbA1c Reduction: 92% of Patients Achieving Glycemic Target and 51% Reaching Normoglycemia Tirzepatide 15 mg delivered the highest rates of glycemic target attainment ever recorded in a Phase 3 randomized controlled trial for T2DM. In SURPASS-1 monotherapy (vs. placebo, n=478, 40 weeks), 92% of tirzepatide 15 mg-treated patients achieved HbA1c below 7.0% (the standard ADA glycemic target) versus 20% with placebo, and 51% reached normoglycemic HbA1c below 5.7% versus 1% with placebo a pharmacological normalization of blood glucose that has not been documented for any other approved antidiabetic agent used as monotherapy. In SURPASS-2 (vs. semaglutide 1 mg, n=1,879), tirzepatide 15 mg produced –2.30% HbA1c reduction versus –1.86% for semaglutide 1 mg (p<0.001). In SURPASS-3 (vs. insulin degludec, n=1,444), tirzepatide 15 mg achieved –2.37% HbA1c reduction versus –1.34% for optimally titrated insulin degludec outperforming best-practice insulin therapy by a margin of 1.03 percentage points in mean HbA1c reduction while simultaneously producing 12.9 kg of body weight loss versus 2.3 kg of weight gain with insulin. |
22.5% Mean Body Weight Loss in Non-Diabetic Obesity the Largest Pharmacological Weight Reduction in Clinical Trial History The 22.5% mean body weight reduction produced by tirzepatide 15 mg in the SURMOUNT-1 trial (n=2,539, 72 weeks) is the largest mean pharmacological weight loss ever documented in a randomized, placebo-controlled trial of any approved or investigational anti-obesity agent surpassing all prior incretin-based therapies, including semaglutide 2.4 mg (Wegovy), which produced a 14.9% mean weight loss in the STEP-1 trial. At tirzepatide 15 mg in SURMOUNT-1: 48% of patients achieved ≥25% body weight loss; 57% achieved ≥20% weight loss; 89% achieved ≥5% weight loss all versus 1%, 3%, and 35% respectively with placebo. The mean absolute weight loss of approximately 23.6 kg at 72 weeks positions tirzepatide 15 mg as the first pharmacological agent to approach bariatric surgical outcomes in average weight reduction, fundamentally repositioning obesity pharmacotherapy and establishing tirzepatide 15 mg as the benchmark against which all subsequent anti-obesity agents are measured. |
Triple-Indication Approval and Maximum Cardiovascular, Metabolic, and OSA Benefits at the Ceiling Dose Tirzepatide 15 mg is the only approved pharmacological agent with simultaneous reference-label indication for three major cardiometabolic conditions: type 2 diabetes mellitus, chronic weight management (obesity and overweight with comorbidities), and moderate to severe obstructive sleep apnea with obesity making Tirzide 15 MG the uniquely comprehensive cardiometabolic treatment option for patients with overlapping T2DM, obesity, and OSA, a cluster of comorbidities that is both highly prevalent in endocrinology practice and highly amenable to the multi-system metabolic correction that tirzepatide’s dual GIP/GLP-1 receptor agonism provides at its maximum dose. In SURMOUNT-OSA, tirzepatide 15 mg significantly reduced the apnea-hypopnea index (AHI), improved oxygen desaturation index, reduced hypoxic burden, and improved patient-reported sleep quality establishing that the maximum weight-reducing effect of tirzepatide 15 mg translates directly and measurably into OSA disease burden reduction across multiple clinical endpoints simultaneously. |
Drug Interactions and Important Safety Information for Tirzide 15 MG (Tirzepatide)
The most clinically significant drug interaction categories for tirzepatide at the 15 mg maximum maintenance dose involve insulin and insulin secretagogues, orally administered medications with narrow therapeutic windows or absorption-rate-dependent pharmacokinetics, and agents that independently modulate glycemic control or body weight. At the 15 mg ceiling dose, tirzepatide’s pharmacodynamic interactions with co-administered antidiabetic agents are at their highest magnitude across the entire dose range maximum dual GIP and GLP-1 receptor agonism delivers maximum glucose-dependent insulin secretagogue effects and maximum gastric emptying delay, requiring the most rigorous co-medication dose management of any tirzepatide dose level.
Tirzepatide’s metabolic elimination pathway proteolytic cleavage of the peptide backbone, beta-oxidation of the C20 fatty diacid moiety, and amide hydrolysis is entirely CYP enzyme-independent, meaning that tirzepatide 15 mg carries no clinically relevant CYP3A4, CYP2C9, CYP2D6, or CYP1A2-mediated drug-drug interaction risk a meaningful pharmacokinetic advantage over most oral antidiabetic agents whose elimination involves hepatic CYP metabolism and whose drug interaction profiles are correspondingly more complex.
Insulin and insulin secretagogues (sulfonylureas and meglitinides) represent the highest-priority and most pharmacodynamically consequential interaction at tirzepatide 15 mg. At the maximum dose, tirzepatide’s glucose-dependent insulin secretagogue effect reaches its pharmacological ceiling; co-administration with basal insulin (insulin glargine, insulin degludec), prandial insulin, or pre-mixed insulin at unchanged doses carries a high risk of clinically significant hypoglycemia including severe hypoglycemia requiring third-party assistance.
In clinical practice, insulin dose reductions of 40 to 60% or greater are commonly required when tirzepatide is titrated to 15 mg in patients on concomitant insulin therapy, guided by continuous or structured blood glucose monitoring and dose-adjustment protocols agreed in advance with the prescribing endocrinologist or diabetologist. Some patients, particularly those with longer T2DM duration and residual beta-cell function, may be able to discontinue basal insulin entirely when tirzepatide reaches the 15 mg dose.
Sulfonylureas (glibenclamide, glipizide, glimepiride, gliclazide, gliquidone) and meglitinides (repaglinide, nateglinide) stimulate insulin secretion in a glucose-independent manner; their combination with maximum-dose tirzepatide’s GIP/GLP-1-mediated insulin secretagogue effect creates the most significant pharmacodynamic hypoglycemia risk across the tirzepatide dose range; dose reduction to the minimum effective sulfonylurea or meglitinide dose or substitution with a hypoglycemia-neutral agent must be implemented before or immediately upon escalation to tirzepatide 15 mg. Orally administered medications with absorption-rate-sensitive pharmacokinetics are maximally affected at tirzepatide 15 mg’s established and consistent gastric emptying delay: oral hormonal contraceptives (a barrier contraceptive method is recommended for 4 weeks after each tirzepatide dose escalation, including the 12.5 mg to 15 mg step); levothyroxine (TSH must be reassessed 6 to 8 weeks after escalation to 15 mg); oral immunosuppressants with narrow therapeutic windows (cyclosporine, tacrolimus) whose trough levels should be monitored at escalation to 15 mg; and oral antibiotics requiring rapid systemic absorption for time-critical infections. Clinicians co-prescribing companion antidiabetic agents alongside Tirzide 15 MG can review the complete diabetes medicines range at Mediaid Pharmacy.
Warfarin and vitamin K antagonists with narrow therapeutic indices require the most frequent INR monitoring at tirzepatide 15 mg the maximum gastric emptying delay at this dose may produce the largest effect on warfarin absorption kinetics of any tirzepatide dose level, requiring weekly INR checks in the first 4 to 6 weeks after reaching 15 mg until anticoagulant stability is re-established.
Direct oral anticoagulants (DOACs) including rivaroxaban and edoxaban have absorption-dependent bioavailability that may be affected by maximum-dose gastric emptying delay; clinical monitoring for signs of thromboembolism or unexpected bleeding is warranted at 15 mg in high-risk patients. Corticosteroids (oral, parenteral, intra-articular, and high-potency topical formulations with systemic absorption) exert the most clinically challenging glycemic interaction at tirzepatide 15 mg corticosteroid-induced insulin resistance and hepatic glycogenolysis substantially antagonize tirzepatide’s maximum glycemic control, often requiring temporary addition or intensification of antidiabetic therapy during systemic corticosteroid courses; blood glucose monitoring must be intensified whenever corticosteroids are started, dose-adjusted, or discontinued.
Atypical antipsychotics (olanzapine, clozapine, risperidone, aripiprazole) promote weight gain and insulin resistance through dopaminergic and histaminergic mechanisms; tirzepatide 15 mg’s maximum weight-reducing and insulin-sensitizing effects partially offset these metabolic consequences in most patients, but the combination requires structured metabolic monitoring.
Alcohol substantially amplifies hypoglycemia risk at tirzepatide 15 mg, particularly in patients on concomitant insulin or sulfonylurea; patients must be counselled to minimize or eliminate alcohol consumption throughout maximum-dose maintenance. Patients must provide a complete medication list to their prescribing endocrinologist before and throughout Tirzide 15 MG treatment. Providers sourcing companion Everest Pharmaceuticals medicines alongside Tirzide 15 MG can explore the full Everest Pharmaceuticals medicines range at Mediaid Pharmacy.
Side Effects and Precautions of Tirzide 15 MG (Tirzepatide)
|
Common Side Effects Nausea (the most frequently reported adverse event at the 15 mg maximum dose; at this level, patients have accumulated at least 20 weeks of prior tirzepatide exposure across five preceding dose steps, providing significant GI adaptation that reduces nausea severity relative to earlier titration phases; nonetheless, some patients experience renewed or intensified nausea at the 12.5 mg to 15 mg escalation step, managed by eating smaller, lower-fat meals and injecting at bedtime where clinically feasible) Diarrhea (reported in ≥5% of patients on tirzepatide 15 mg; generally transient at dose escalation; adequate hydration and dietary adjustment support management throughout 15 mg maintenance) Vomiting (most likely in the first 2 to 4 weeks after escalation from 12.5 mg to 15 mg; eating slowly, reducing meal size, and avoiding high-fat and high-sugar trigger foods during the escalation adaptation window minimise frequency and severity) Constipation (notably more frequent at the 15 mg maximum dose than at lower tirzepatide doses; proactive dietary fibre supplementation of at least 25 to 30 g per day, fluid intake of ≥2 litres daily, and regular physical activity are recommended throughout maximum-dose maintenance; osmotic laxatives may be required in some patients) Sustained and pronounced appetite suppression and reduced caloric intake (the strongest and most consistent pharmacodynamic appetite-suppressing effect across the tirzepatide dose range occurs at 15 mg; patients must receive structured dietitian guidance to ensure adequate protein intake typically ≥1.2 g/kg ideal body weight per day and sufficient micronutrient consumption despite the significant appetite reduction and caloric deficit at this dose level) Abdominal pain, bloating, and dyspepsia (persistent at maximum-dose maintenance due to the ceiling-level gastric emptying delay; generally mild to moderate and manageable; tends to reduce gradually with sustained 15 mg exposure as gastric motility adapts) Injection site reactions (erythema, pruritus, swelling, or nodule at the injection site; rotate injection sites abdomen, thigh, upper arm with each weekly dose throughout maximum-dose maintenance; inject away from lipohypertrophic tissue; allow syringe to reach room temperature before injecting) Hypoglycemia (rare as 15 mg monotherapy; maximum risk across the tirzepatide dose range when combined with insulin or sulfonylurea; structured pre-emptive co-medication dose reduction protocols are mandatory before escalation to 15 mg in all patients on insulin or insulin secretagogues) Gastroesophageal reflux, belching, flatulence, and delayed gastric emptying symptoms (more consistently reported at maximum maintenance doses than at lower dose levels; elevating the head of the bed 30 degrees during sleep, avoiding late evening meals, and eliminating carbonated beverages reduces symptom burden) |
Serious Warnings and Precautions Thyroid C-cell tumors (medullary thyroid carcinoma): tirzepatide caused dose-dependent thyroid C-cell tumors including medullary thyroid carcinoma in rodent studies, with the highest exposures corresponding to the 15 mg maximum dose level. The risk to humans has not been confirmed but cannot be excluded at any dose, and the maximum dose requires the most careful thyroid risk counselling of any tirzepatide strength. Tirzide 15 MG is absolutely contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). All patients must be counselled about the thyroid tumor risk signal before initiating maximum-dose therapy and must report any signs or symptoms of potential thyroid malignancy including new neck mass, progressive dysphagia, persistent hoarseness, unexplained cough, or new-onset shortness of breath to their prescribing endocrinologist without delay throughout the 15 mg maintenance period. Pancreatitis: acute pancreatitis including hemorrhagic and necrotizing cases has been reported with GLP-1 receptor agonists and with tirzepatide across the dose range. Discontinue Tirzide 15 MG immediately if pancreatitis is clinically suspected (persistent severe epigastric or mid-abdominal pain, radiation to the back, nausea, vomiting, or serum lipase or amylase elevation greater than 3 times the upper limit of normal). Tirzepatide must not be restarted at any dose if acute pancreatitis is confirmed by imaging or clinical assessment. A personal history of acute pancreatitis is a relative contraindication requiring documented specialist benefit-risk assessment before 15 mg maintenance is initiated. Acute kidney injury (AKI): the sustained nausea, vomiting, and diarrhea associated with tirzepatide 15 mg maximum-dose maintenance can cause clinically significant volume depletion and AKI, particularly in patients with CKD stage 3 to 5, elderly patients, patients receiving ACE inhibitors, ARBs, or NSAIDs, and those with reduced hemodynamic reserve. Renal function must be checked before escalation to 15 mg, reassessed at steady state (approximately 4 to 5 weeks at 15 mg), and monitored during any episode of significant GI adverse events; Tirzide 15 MG should be temporarily withheld until the patient is adequately rehydrated and renal function has returned to baseline. Diabetic retinopathy complications: the HbA1c reductions produced at tirzepatide 15 mg among the largest of any approved antidiabetic agent are associated with the highest risk of rapid-correction-related worsening of diabetic retinopathy across the tirzepatide dose range. Patients with pre-existing proliferative diabetic retinopathy or severe non-proliferative retinopathy require ophthalmological baseline assessment before escalation to 15 mg and structured retinal monitoring during the period of maximum glycemic correction, typically the first 12 months at the maximum dose. Hypersensitivity reactions: serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with tirzepatide. Permanently discontinue Tirzide 15 MG if a serious systemic hypersensitivity reaction occurs. Patients with any prior hypersensitivity reaction to tirzepatide INN or any excipient in the Tirzide formulation must not receive this product at any dose. Embryo-fetal toxicity: tirzepatide is not recommended during pregnancy due to potential fetal harm. At the 15 mg maximum dose, systemic tirzepatide exposure is highest across the dose range, requiring the most careful contraception and pre-conception clearance planning. Females of reproductive potential must use effective non-hormonal contraception during Tirzide 15 MG treatment and for at least 2 weeks after the final dose; prescribers strongly recommend discontinuing tirzepatide at least 2 months before a planned pregnancy to allow complete systemic clearance at the maximum dose. Women using oral hormonal contraceptives must add a non-hormonal barrier method for 4 weeks after escalation from 12.5 mg to 15 mg. Breastfeeding is not recommended during treatment. Consult your prescribing endocrinologist or obstetrician before initiating or continuing Tirzide 15 MG if pregnant, planning a pregnancy, or currently breastfeeding. |
Who Should Use Tirzide 15 MG (Tirzepatide)?
Tirzide 15 MG (Tirzepatide) is the maximum-dose product within the tirzepatide treatment program and is prescribed exclusively for patients who have completed the full structured titration sequence from 2.5 mg through 5 mg, 7.5 mg, 10 mg, and 12.5 mg and for whom the prescribing endocrinologist or diabetologist determines that escalation to the ceiling dose is clinically warranted. Three distinct patient groups are indicated for Tirzide 15 MG: First, adults with T2DM who have not achieved their individualized HbA1c target after ≥4 weeks at steady-state tirzepatide 12.5 mg, and for whom maximum glycemic control is required to prevent or delay the micro- and macrovascular complications of poorly controlled diabetes including patients with HbA1c substantially above target despite structured titration through lower doses, patients with complex insulin-resistant T2DM requiring the maximum dual GIP/GLP-1 receptor agonism to achieve glycemic normalization, and patients in whom the prescribing endocrinologist has determined from the outset of therapy that the treatment plan targets the 15 mg maximum efficacy ceiling.
Second, adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with weight-related comorbidities for whom chronic weight management with tirzepatide has been prescribed and for whom the 22.5% mean body weight reduction achievable at tirzepatide 15 mg rather than the 15% to 19.5% achievable at lower doses is required to achieve a clinically meaningful weight management target, including patients with severe obesity (BMI ≥40 kg/m²), patients with multiple obesity-related comorbidities requiring maximum weight reduction, and patients for whom the degree of weight loss at lower maintenance doses has been clinically insufficient after adequate titration periods.
Third, adults with moderate to severe OSA and obesity for whom tirzepatide 15 mg has been selected as the target maintenance dose in the OSA indication, where the maximum weight-reducing effect of the ceiling dose is expected to deliver the greatest AHI reduction and sleep quality improvement. Tirzide 15 MG is absolutely contraindicated in patients with personal or family history of MTC or MEN2; in patients with type 1 diabetes mellitus; in individuals with confirmed hypersensitivity to tirzepatide INN or any product excipient; and is not suitable as a starting dose under any circumstances all patients must complete the mandatory structured titration from 2.5 mg before reaching 15 mg. Before escalating to Tirzide 15 MG, prescribers must document: HbA1c and/or body weight response at 12.5 mg confirming the need for maximum dose escalation; renal function assessment confirming AKI risk stratification; structured hypoglycemia management protocols for patients on concomitant insulin or sulfonylurea; ophthalmological status in patients with diabetic retinopathy; and a documented risk-benefit discussion with the patient covering the thyroid C-cell tumor signal, GI adverse event profile, and reproductive safety requirements at maximum dose. For patients requiring companion antidiabetic medicines, cardiovascular agents, or the complete Everest Pharmaceuticals product range alongside their tirzepatide 15 mg regimen, the Mediaid Pharmacy Everest Pharmaceuticals medicines portfolio and the comprehensive diabetes medicines collection offer a complete selection available for worldwide delivery.
Global Supplier: Mediaid Pharmacy Worldwide Shipping for Tirzide 15 MG (Tirzepatide)
Mediaid Pharmacy is a Dhaka-based supplier of specialty and diabetes medicines with worldwide shipping to patients, clinics, hospitals, and distributors across all regions. Tirzide 15 MG (Tirzepatide), manufactured by Everest Pharmaceuticals Ltd. in Bangladesh, is available as 1 pre-filled syringe per box (with alcohol pad and first aid bandage), supported by pricing quotations, stock confirmation, full product documentation, and end-to-end international delivery tracking for every order. Endocrinology centers, diabetology clinics, obesity medicine and bariatric programs, sleep medicine centers, hospital formulary managers, international distributors, and patients prescribed maximum-dose tirzepatide can contact the Mediaid Pharmacy team through WhatsApp, phone, or WeChat for all inquiries regarding Tirzide 15 MG Tirzepatide stock availability, current pricing, and international delivery timelines to their country. Buyers sourcing tirzepatide 15 mg for maximum-dose maintenance patients, establishing tirzepatide prescribing programs across the complete dosing range (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg), or consolidating multiple tirzepatide strengths with companion diabetes or cardiometabolic medicines in a single international shipment can browse the complete tirzepatide medicines collection and the broader diabetes medicines collection at Mediaid Pharmacy before submitting a consolidated quotation request.
Why Choose Tirzide 15 MG (Tirzepatide) from Mediaid Pharmacy?
Tirzide 15 MG (Tirzepatide) provides endocrinologists, diabetologists, obesity medicine specialists, and sleep physicians with the reference-label maximum dose of tirzepatide the ceiling strength that delivers the most extensive clinical evidence base of any tirzepatide dose, anchoring the SURPASS and SURMOUNT Phase 3 programs with efficacy outcomes that have redefined expectations in both T2DM and obesity pharmacotherapy. Tirzepatide 15 mg is the dose that achieved 92% of T2DM patients reaching HbA1c below 7.0% as monotherapy; the dose that produced 22.5% mean body weight loss in non-diabetic obesity the largest pharmacological weight reduction ever documented in a randomized controlled trial; the dose that outperformed both optimally titrated basal insulin and the leading GLP-1 receptor agonist in direct head-to-head Phase 3 comparisons; and the dose that opened the entirely new indication of moderate to severe obstructive sleep apnea with obesity, establishing tirzepatide as the first and only pharmacological treatment approved for OSA.
All of these maximum-efficacy outcomes are documented specifically at the 15 mg dose the only dose that achieves peak dual GIP and GLP-1 receptor agonism at the pharmacological ceiling of the twincretin mechanism, the mechanism that no selective GLP-1 receptor agonist replicates. Tirzide 15 MG is manufactured by Everest Pharmaceuticals Ltd., a Bangladesh-based pharmaceutical manufacturer, and supplied as an individually boxed pre-filled syringe with alcohol pad and first aid bandage a complete, ready-to-inject once-weekly kit with no reconstitution, pen dialing, or dose calculation required, supporting uninterrupted once-weekly maximum-dose subcutaneous administration for the long-term continuous therapy that delivers tirzepatide’s peak cardiometabolic, glycemic, and weight management outcomes. Mediaid Pharmacy supplies Tirzide 15 MG with full product documentation, specialist supply coordination, and worldwide shipping from Dhaka. To source the complete Tirzide dosing range, Everest Pharmaceuticals companion medicines, or a comprehensive diabetes and cardiometabolic medicine formulary alongside Tirzide 15 MG, visit the Mediaid Pharmacy Everest Pharmaceuticals medicines section and contact the team for a personalized quotation.
Frequently Asked Questions About Tirzide 15 MG (Tirzepatide)
What is Tirzide 15 MG (Tirzepatide) used for?
Tirzide 15 MG (Tirzepatide) is the maximum approved dose of a dual GIP and GLP-1 receptor agonist (twincretin), used once weekly subcutaneously across three approved indications: (1) type 2 diabetes mellitus (T2DM) in adults as an adjunct to diet and exercise where tirzepatide 15 mg produced –2.30% HbA1c reduction in SURPASS-2, with 92% of patients reaching HbA1c below 7.0% and 51% reaching normoglycemia below 5.7% in SURPASS-1 monotherapy; (2) chronic weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity where tirzepatide 15 mg produced a mean 22.5% body weight reduction versus 2.4% placebo in SURMOUNT-1, the largest pharmacological weight loss ever recorded in a randomized controlled trial; and (3) moderate to severe obstructive sleep apnea (OSA) in adults with obesity where 15 mg is one of the two specifically recommended maintenance doses. Tirzide 15 MG is available at Mediaid Pharmacy with worldwide shipping.
What is the generic name of Tirzide 15 MG?
The generic name of Tirzide 15 MG is tirzepatide INN. Tirzide is the brand name registered by Everest Pharmaceuticals Ltd. in Bangladesh. Tirzide 15 MG is supplied as a solution for injection in a pre-filled syringe (1 syringe/box with alcohol pad and first aid bandage), delivering 15 mg of tirzepatide in 0.5 mL subcutaneously once weekly. The originator reference brands for tirzepatide are Mounjaro (by Eli Lilly, for T2DM) and Zepbound (by Eli Lilly, for chronic weight management and obstructive sleep apnea). Mediaid Pharmacy distributes Tirzide 15 MG globally with worldwide shipping to patients, healthcare providers, hospitals, and specialist clinics.
Can I start tirzepatide therapy directly at 15 mg?
No. Tirzepatide 15 mg is the maximum maintenance dose and must never be administered as the first dose of tirzepatide therapy. The reference prescribing information requires a structured titration schedule beginning at 2.5 mg once weekly for 4 weeks, then 5 mg for ≥4 weeks, then 7.5 mg for ≥4 weeks, then 10 mg for ≥4 weeks, then 12.5 mg for ≥4 weeks, and only then 15 mg a minimum titration period of 20 weeks (5 months) before the ceiling dose is introduced. Initiating tirzepatide directly at 15 mg without prior dose escalation would cause severe and potentially treatment-ending gastrointestinal adverse events (nausea, vomiting, diarrhea) in the overwhelming majority of patients, as the gastric emptying-slowing mechanism of tirzepatide at maximum dose requires progressive GI adaptation through the full titration sequence. All patients who require the 15 mg ceiling dose must complete the full escalation pathway, beginning with the 2.5 mg initiation dose available in the complete tirzepatide injection range at Mediaid Pharmacy.
How much weight can you lose on tirzepatide 15 mg?
Tirzepatide 15 mg produced the largest mean pharmacological weight loss ever documented in a randomized controlled trial. In the SURMOUNT-1 Phase 3 trial (2,539 adults with obesity or overweight without T2DM, 72 weeks), tirzepatide 15 mg achieved a mean body weight reduction of 22.5% from baseline versus 2.4% with placebo an approximately 23.6 kg mean absolute weight loss with 48% of participants achieving ≥25% body weight loss, 57% achieving ≥20%, and 89% achieving ≥5%. In SURMOUNT-2 (adults with T2DM and obesity, 72 weeks), tirzepatide 15 mg produced 15.7% mean weight loss versus 3.3% placebo. In the T2DM trial SURPASS-2 (40 weeks), tirzepatide 15 mg produced a mean weight reduction of 11.2 kg versus 5.7 kg with semaglutide 1 mg. These outcomes represent the highest weight losses ever documented for a pharmacological agent approved for chronic weight management, with results from tirzepatide 15 mg approaching those of bariatric surgical procedures in mean percentage weight reduction across study populations.
What is the difference between Tirzide 15 MG (Tirzepatide) and Mounjaro or Zepbound?
Tirzide 15 MG (tirzepatide) manufactured by Everest Pharmaceuticals Ltd. in Bangladesh and Mounjaro or Zepbound (tirzepatide) manufactured by Eli Lilly and Company contain the same active ingredient tirzepatide INN as a subcutaneous injection for once-weekly administration. Mounjaro is the originator brand name approved by the FDA for tirzepatide in type 2 diabetes; Zepbound is the Eli Lilly brand name for tirzepatide in chronic weight management and obstructive sleep apnea. Tirzide 15 MG is the Everest Pharmaceuticals-branded formulation at the maximum 15 mg dose, supplied in a pre-filled syringe (1 syringe/box with alcohol pad and first aid bandage) and distributed globally by Mediaid Pharmacy. The same reference titration schedule (beginning at 2.5 mg) and the same maximum dose of 15 mg apply to all tirzepatide brands. Confirm prescribing requirements and local regulatory status with your treating endocrinologist and the relevant regulatory authority before initiating Tirzide 15 MG therapy.
What are the side effects of Tirzide 15 MG (Tirzepatide)?
The most common side effects of tirzepatide 15 mg are gastrointestinal: nausea, diarrhea, vomiting, constipation (particularly pronounced at the maximum dose), decreased appetite, abdominal pain, dyspepsia, belching, and flatulence. GI adverse events are generally less severe at 15 mg than at lower escalation steps in patients who have completed the structured titration sequence, due to accumulated GI adaptation over ≥20 weeks of prior tirzepatide exposure but constipation is more consistently problematic at the 15 mg ceiling dose than at lower maintenance levels and requires proactive dietary fibre management. Injection site reactions are managed through site rotation. Hypoglycemia risk is at its maximum across the tirzepatide dose range when 15 mg is combined with insulin or sulfonylurea, requiring structured pre-emptive co-medication dose reduction. Serious adverse effects include acute pancreatitis, acute kidney injury (from dehydration secondary to GI side effects), serious hypersensitivity reactions (anaphylaxis, angioedema), worsening of diabetic retinopathy (particularly at the maximum glycemic reduction achievable at 15 mg), and a thyroid C-cell tumor risk signal based on rodent studies the basis for absolute contraindication in MTC or MEN2 history patients. Always discuss your individual benefit-risk profile with your prescribing endocrinologist before and throughout Tirzide 15 MG treatment.
Is tirzepatide 15 mg approved for obstructive sleep apnea?
Yes. Tirzepatide 15 mg is approved for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity, where it is designated as one of the two specifically recommended maintenance doses (alongside 10 mg) in the reference prescribing information. Tirzepatide is the first pharmacological agent ever approved for OSA treatment. In the SURMOUNT-OSA Phase 3 trial, tirzepatide significantly reduced the apnea-hypopnea index (AHI) the primary clinical endpoint versus placebo, alongside improvements in oxygen desaturation index, nocturnal oxygen saturation nadir, hypoxic burden, and patient-reported sleep-related quality of life. The OSA approval at 15 mg is mechanistically explained by the maximum weight reduction achievable at this dose since upper airway obstruction in obese patients is primarily driven by adipose tissue deposition in pharyngeal structures, and tirzepatide 15 mg’s 22.5% mean body weight reduction in obesity directly and measurably reduces the anatomical OSA drivers in a weight-proportional relationship. Tirzide 15 MG is available through Mediaid Pharmacy for worldwide delivery for patients prescribed maximum-dose tirzepatide for the OSA indication.
Can I order Tirzide 15 MG (Tirzepatide) online with worldwide shipping?
Yes. Mediaid Pharmacy supplies Tirzide 15 MG (Tirzepatide) to patients and healthcare providers globally. Contact Mediaid Pharmacy via WhatsApp, phone, or WeChat at +8801773428128, or email info@mediaidpharmacy.com for pricing, current stock availability, and international delivery details for your country.
Order Tirzide 15 MG (Tirzepatide) with Worldwide Shipping
Phone / WhatsApp / WeChat: +8801773428128 | Email: info@mediaidpharmacy.com
Reviews
There are no reviews yet.